Heron Therapeutics (HRTX) EBT (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly EBT came in at -$7.4 million in Q1 2026, down 416.05% YoY from $2.3 million in Q1 2025, and down 42.18% on a QoQ basis from -$5.2 million in Q4 2025.
Heron Therapeutics (HRTX) EBT (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 17 years of EBT data on file, last reported at -$7.4 million in Q1 2026.
- Quarterly EBT fell 416.05% year-over-year to -$7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$22.2 million (down 261.55% YoY) and the FY2025 annual result came in at -$415.6 million, down 2866.37% from the prior year.
- EBT declined to -$7.4 million in Q1 2026, from -$5.2 million in the prior quarter.
- In the past five years, EBT ranged from a high of $4.1 million in Q4 2024 to a low of -$63.6 million in Q1 2022.
- A 5-year average of -$19.2 million and a median of -$7.4 million in 2026 frame the typical range for EBT.
- Annual changes were most pronounced in 2025 — EBT surged 141.69% — and 2026, when it tumbled 416.05%.
- Tracing HRTX's EBT over 5 years: stood at -$21.7 million in 2022, then surged by 44.72% to -$12.0 million in 2023, then soared by 133.93% to $4.1 million in 2024, then plunged by 228.1% to -$5.2 million in 2025, then tumbled by 42.18% to -$7.4 million in 2026.
- The last three EBT figures came in at -$7.4 million (Q1 2026), -$5.2 million (Q4 2025), and -$7.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Heron Therapeutics | 58.32 Mn | 15.65 Mn | 26.09 Mn | -2.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.03 Mn |
| Mar 31, 2026 | -7.40 Mn |
| Dec 31, 2025 | -5.21 Mn |
| Sep 30, 2025 | -7.19 Mn |
| Jun 30, 2025 | -2.44 Mn |
| Mar 31, 2025 | 2.34 Mn |
| Dec 31, 2024 | 4.06 Mn |
| Sep 30, 2024 | -5.21 Mn |
| Jun 30, 2024 | -7.35 Mn |
| Mar 31, 2024 | -5.62 Mn |
| Dec 31, 2023 | -11.98 Mn |
| Sep 30, 2023 | -25.42 Mn |
| Jun 30, 2023 | -43.42 Mn |
| Mar 31, 2023 | -33.74 Mn |
| Dec 31, 2022 | -21.67 Mn |
| Sep 30, 2022 | -42.63 Mn |
| Jun 30, 2022 | -50.20 Mn |
| Mar 31, 2022 | -63.63 Mn |
| Dec 31, 2021 | -53.30 Mn |
| Sep 30, 2021 | -52.37 Mn |